Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers. [electronic resource]
Producer: 20190319Description: e0204973 p. digitalISSN:- 1932-6203
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- adverse effects
- Biomarkers, Tumor -- metabolism
- Breast Neoplasms -- drug therapy
- Delayed-Action Preparations
- Female
- Gonanes -- adverse effects
- Half-Life
- Humans
- Middle Aged
- Nausea -- etiology
- Neoplasm Metastasis
- Neoplasm Recurrence, Local
- Receptors, Progesterone -- metabolism
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.